Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors.

The bradykinin analog, RMP-7, was investigated for its ability to selectively increase uptake of molecular tracers in RG2 glial tumors. When infused in low doses (0.1 microgram/kg/min) through the intracarotid artery ipsilateral to RG2 gliomas in rats, RMP-7 significantly increased the permeability of tumor capillaries to methotrexate and to four other tracers of varying molecular weights, compared to intracarotid infusion of vehicle alone. Tracers used to examine permeability included radiolabeled alpha-aminoisobutyric acid (M(r) 103 D), sucrose (M(r) 342 D), methotrexate (M(r) 454.5 D), inulin (M(r) 5000 D), and dextran (M(r) 70,000 D). Permeability was expressed as the unidirectional transfer constant, Ki (microliters/gm/min). The permeability (Ki) of tumors in the RMP-7 group compared to the vehicle control group was as follows: alpha-aminoisobutyric acid, 35.3 +/- 9.11 versus 12.7 +/- 4.56 (p < 0.001); sucrose, 16.5 +/- 3.83 versus 9.28 +/- 3.12 (p < 0.05); methotrexate, 26.3 +/- 10.3 versus 8.98 +/- 6.78 (p < 0.005); inulin, 13.5 +/- 3.23 versus 6.55 +/- 4.32 (p < 0.005); dextran, 15.2 +/- 3.42 versus 1.47 +/- 1.24 (p < 0.001). The permeability of RG2 gliomas to high-molecular-weight dextran (70,000 D) was 10.3-fold higher in the RMP-7 group than in the vehicle control group. Intracarotid infusion of RMP-7 did not significantly increase the blood volume in tumor or brain tissue. The permeability of normal brain capillaries was unaffected by intracarotid infusion of 0.1 microgram/kg/min RMP-7 relative to that achieved in tumor. These data support the idea that intracarotid infusion of RMP-7 will be a useful technique for selective delivery of antitumor compounds to brain tumors.

[1]  E. M. Renkin,et al.  Effects of histamine and some other substances on molecular selectivity of the capillary wall to plasma proteins and dextran. , 1974, Microvascular research.

[2]  K D Pettigrew,et al.  Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. , 1978, The American journal of physiology.

[3]  K. Black,et al.  Increased opening of blood-tumour barrier by leukotriene C4 is dependent on size of molecules. , 1992, Neurological research.

[4]  Fenstermacher Jd,et al.  Theoretic limitations of intracarotid infusions in brain tumor chemotherapy. , 1977 .

[5]  D. Robertson,et al.  Pharmacological Modification of Bradykinin Induced Breakdown of the Blood-brain Barrier , 1986, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[6]  S. Rapoport,et al.  Differential blood-brain barrier permeabilities to [14C]sucrose and [3H]inulin after osmotic opening in the rat , 1983, Experimental Neurology.

[7]  E P Frenkel,et al.  Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Rapoport,et al.  Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. , 1984, Federation proceedings.

[9]  M. Brightman,et al.  Morphology of blood-brain interfaces. , 1977, Experimental eye research.

[10]  K. Pettigrew,et al.  A heterogenous, pore-vesicle membrane model for protein transfer from blood to cerebrospinal fluid at the choroid plexus. , 1979, Microvascular research.

[11]  K. Black,et al.  Selective blood-tumor barrier disruption by leukotrienes. , 1992, Journal of neurosurgery.

[12]  K. Black,et al.  Selective opening of the blood-tumour barrier by intracarotid infusion of leukotriene C4. , 1990, Acta neurochirurgica. Supplementum.

[13]  K. Black,et al.  Increased leukotriene C4 and vasogenic edema surrounding brain tumors in humans , 1986, Annals of neurology.

[14]  E P Frenkel,et al.  Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening. , 1984, Neurosurgery.

[15]  C. Pirola,et al.  Central bradykininergic system in normotensive and hypertensive rats. , 1992, Clinical science.

[16]  W. T. Shults,et al.  Maculopathy associated with combination chemotherapy and osmotic opening of the blood-brain barrier. , 1986, American journal of ophthalmology.

[17]  F. Hazama,et al.  NEUROTOXICITY OF VINCRISTINE AFTER THE OSMOTIC OPENING OF THE BLOOD‐BRAIN BARRIER , 1983, Neuropathology and applied neurobiology.

[18]  R. Fishman,et al.  Induction of brain edema following intracerebral injection of arachidonic acid , 1983, Annals of neurology.

[19]  Waggener Jd,et al.  Transendothelial vesicular transport of protein following compression injury to the spinal cord. , 1976 .

[20]  J. Minna,et al.  Osmotic blood-brain barrier modification: monoclonal antibody, albumin, and methotrexate delivery to cerebrospinal fluid and brain. , 1985, Neurosurgery.

[21]  Y. Z. Ziylan,et al.  Effect of Dexamethasone on Transport of α‐Aminoisobutyric Acid and Sucrose Across the Blood‐Brain Barrier , 1988, Journal of neurochemistry.

[22]  E. M. Renkin,et al.  Transport of large molecules from plasma to interstitial fluid and lymph in dogs. , 1970, The American journal of physiology.

[23]  K. Black,et al.  Selective opening of the blood-tumor barrier by intracarotid infusion of leukotriene C4. , 1990, Journal of neurosurgery.

[24]  S. Rennard,et al.  Role of peptidases in bradykinin-induced increase in vascular permeability in vivo. , 1992, Circulation research.

[25]  K. Black,et al.  Bradykinin Selectively Opens Blood-Tumor Barrier in Experimental Brain Tumors , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[26]  D. Bigner,et al.  Permeability of Different Experimental Brain Tumor Models to Horseradish Peroxidase , 1982, Journal of neuropathology and experimental neurology.